Protective effects of Tat-DJ-1 protein against streptozotocin-induced diabetes in a mice model

BMB Rep. 2018 Jul;51(7):362-367. doi: 10.5483/bmbrep.2018.51.7.101.

Abstract

A major feature of type 1 diabetes mellitus (T1DM) is hyperglycemia and dysfunction of pancreatic β-cells. In a previous study, we have shown that Tat-DJ-1 protein inhibits pancreatic RINm5F β-cell death caused by oxidative stress. In this study, we examined effects of Tat-DJ-1 protein on streptozotocin (STZ)-induced diabetic mice. Wild type (WT) Tat-DJ-1 protein transduced into pancreas where it markedly inhibited pancreatic β-cell destruction and regulated levels of serum parameters including insulin, alkaline phosphatase (ALP), and free fatty acid (FFA) secretion. In addition, transduced WT Tat-DJ-1 protein significantly inhibited the activation of NF-κB and MAPK (ERK and p38) expression as well as expression of COX-2 and iNOS in STZ exposed pancreas. In contrast, treatment with C106A mutant Tat-DJ-1 protein showed no protective effects. Collectively, our results indicate that WT Tat-DJ-1 protein can significantly ameliorate pancreatic tissues in STZ-induced diabetes in mice. [BMB Reports 2018; 51(7): 362-367].

MeSH terms

  • Alkaline Phosphatase / blood
  • Animals
  • Cyclooxygenase 2 / metabolism
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / pathology
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Fatty Acids, Nonesterified / blood
  • Gene Products, tat / genetics*
  • Insulin / blood
  • Insulin-Secreting Cells / cytology
  • Insulin-Secreting Cells / metabolism
  • Male
  • Mice
  • Mice, Inbred ICR
  • NF-kappa B / metabolism
  • Nitric Oxide Synthase Type II / metabolism
  • Oxidative Stress / drug effects
  • Pancreas / metabolism
  • Protective Agents / pharmacology
  • Protective Agents / therapeutic use*
  • Protein Deglycase DJ-1 / genetics*
  • Recombinant Fusion Proteins / biosynthesis
  • Recombinant Fusion Proteins / pharmacology
  • Recombinant Fusion Proteins / therapeutic use*
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Fatty Acids, Nonesterified
  • Gene Products, tat
  • Insulin
  • NF-kappa B
  • Protective Agents
  • Recombinant Fusion Proteins
  • Nitric Oxide Synthase Type II
  • Cyclooxygenase 2
  • Extracellular Signal-Regulated MAP Kinases
  • p38 Mitogen-Activated Protein Kinases
  • Protein Deglycase DJ-1
  • Alkaline Phosphatase